Hypertrophic Cardiomyopathy (Cardiovascular) - Drugs In Development, 2021

August 2021 | 116 pages | ID: H56F05A0454FEN
Global Markets Direct

Abstracts

Hypertrophic Cardiomyopathy (Cardiovascular) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy - Drugs In Development, 2021, provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape.Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the heart to pump blood. Symptoms include chest pain, especially during exercise, sensation of rapid, fluttering or pounding heartbeats and heart murmur. Hypertrophic cardiomyopathy usually is inherited. Treatment includes beta blockers, calcium channel blockers and blood thinners.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypertrophic Cardiomyopathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Hypertrophic Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 3, 1, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Hypertrophic Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hypertrophic Cardiomyopathy (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hypertrophic Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hypertrophic Cardiomyopathy (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hypertrophic Cardiomyopathy (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hypertrophic Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Hypertrophic Cardiomyopathy - Overview
Hypertrophic Cardiomyopathy - Therapeutics Development
Hypertrophic Cardiomyopathy - Therapeutics Assessment
Hypertrophic Cardiomyopathy - Companies Involved in Therapeutics Development
Hypertrophic Cardiomyopathy - Drug Profiles
Hypertrophic Cardiomyopathy - Dormant Projects
Hypertrophic Cardiomyopathy - Discontinued Products
Hypertrophic Cardiomyopathy - Product Development Milestonesh
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Hypertrophic Cardiomyopathy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Hypertrophic Cardiomyopathy - Pipeline by Algomedix Inc, 2021
Hypertrophic Cardiomyopathy - Pipeline by BioMarin Pharmaceutical Inc, 2021
Hypertrophic Cardiomyopathy - Pipeline by Bristol-Myers Squibb Co, 2021
Hypertrophic Cardiomyopathy - Pipeline by C&C BioPharma LLC, 2021
Hypertrophic Cardiomyopathy - Pipeline by Cardior Pharmaceuticals GmbH, 2021
Hypertrophic Cardiomyopathy - Pipeline by Celltrion Inc, 2021
Hypertrophic Cardiomyopathy - Pipeline by Cytokinetics Inc, 2021
Hypertrophic Cardiomyopathy - Pipeline by Genome Biologics UG, 2021
Hypertrophic Cardiomyopathy - Pipeline by Haya Therapeutics SA, 2021
Hypertrophic Cardiomyopathy - Pipeline by Igia Pharmaceuticals Inc, 2021
Hypertrophic Cardiomyopathy - Pipeline by Imbria Pharmaceuticals Inc, 2021
Hypertrophic Cardiomyopathy - Pipeline by Lead Discovery Center GmbH, 2021
Hypertrophic Cardiomyopathy - Pipeline by LEXEO Therapeutics LLC, 2021
Hypertrophic Cardiomyopathy - Pipeline by Novartis AG, 2021
Hypertrophic Cardiomyopathy - Pipeline by Toa Eiyo Ltd, 2021
Hypertrophic Cardiomyopathy - Dormant Projects, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hypertrophic Cardiomyopathy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021